SynthesisDiabetes, obesity & metabolism2018

The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes.

Martin Haluzík et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.